Clinical trials: Solid Tumor Malignancies, Cancer
Advanced Solid Tumors
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy…
- Trial name
- NCT05599984
- Testing
- ABBV-706, Cisplatin, Budigalimab
- Where
- 66 sites in United States, Australia and 8 more
- Volunteers
- 288 people
- Sponsor
- AbbVie
Metastatic Breast Cancer
A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors
The goal of this clinical trial is to learn about the effect of food on absorption of oral Paclitaxel when co- administered with Encequidar tablets in adult patients with tumours.
- Trial name
- NCT07580833
- Testing
- Oral Paclitaxel in combination with Encequidar tablet
- Volunteers
- 46 people
- Sponsor
- Health Hope Pharma
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
This phase I trial studies the side effects of Nozin in preventing respiratory viral infections in patients undergoing stem cell transplant.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Solid Neoplasm
- Trial name
- NCT04060849
- Testing
- Nozin, Best Practice
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumors, Peritoneal Carcinomatosis
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
This phase I trial aims to investigate a potential enhancement of IMP321 immune-activating effects by new routes of administration: direct injection of IMP321 into the tumor tissue; intra-peritoneal therapy; combination of…
- Conditions
- Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma, Urothelial Carcinoma
- Trial name
- INSIGHT (NCT03252938)
- Testing
- IMP321, Avelumab
- Where
- 12 sites in Germany
- Volunteers
- 83 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma
Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors
Recent pre-clinical data provide strong evidence that short-term starvation before the administration of cytostatic drugs for the chemotherapy of solid tumors leads to significantly higher efficacy and lower toxicity levels.
- Conditions
- Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT02607826
- Testing
- Starvation
- Volunteers
- 298 people
- Sponsor
- University Hospital Tuebingen
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Advanced Solid Tumor
ATG-008 Combined With Toripalimab in Advanced Solid Tumors
This is an open-label, single-arm study with dose-escalation and expansion phases to access ATG-008 combined with Toripalimab in patients with advanced solid tumors.
- Trial name
- NCT04337463
- Testing
- ATG-008, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan University
Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as GEM 231 may inhibit the growth of cancer cells and make the tumor more sensitive to…
- Trial name
- NCT00004864
- Testing
- GEM 231, docetaxel
- Where
- United States
- Sponsor
- Montefiore Medical Center
Solid Cancers
A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of orally administered GDC-0941 administered once daily (QD) and twice daily (BID) in the treatment of…
- Trial name
- NCT00876109
- Testing
- GDC-0941
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Genentech, Inc.
Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
- Trial name
- NCT03948763
- Testing
- V941, Pembrolizumab
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Patient Interest in an Integrative Oncology Program at USC Norris Cancer Center: A Single-Institution Needs Assessment
This study assesses patient perspectives on the interest in, feasibility, and acceptability of an Integrative Oncology Program for patients at USC NCCC and HC3 Women's Clinic.
- Trial name
- NCT07306338
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Solid Tumor, Lymphoma
Precision Medicine for Patients With Identified Actionable Mutations
The goal of the current pragmatic trial is to evaluate the impact of a simple method of selecting a treatment approach for identified mutations on participants' progression free survival (PFS).
- Conditions
- Solid Tumor, Lymphoma, Multiple Myeloma, Malignant Neoplasm
- Trial name
- NCT04111107
- Testing
- Investigational Agent, Supportive Care Regimens, Next Gen Sequencing Report
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Wake Forest University Health Sciences
Tumors, Lymphoma
Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)
Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of ridaforolimus in patients with refractory or recurrent malignancies, including myeloma and lymphoma.
- Conditions
- Tumors, Lymphoma, Multiple Myeloma
- Trial name
- NCT00060632
- Testing
- ridaforolimus
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Stomach Cancer
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors…
- Conditions
- Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
- Trial name
- NCT06821048
- Testing
- Intraperitoneal infusion of FAST CEA-targeted CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Weijia Fang, MD
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well they work in treating patients with cancers that have come back (relapsed) or does not respond to treatment…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma
- Trial name
- NCT04500548
- Testing
- Biospecimen Collection, Ipilimumab, Nivolumab
- Where
- 9 sites in United States, Canada
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00726830
- Testing
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Study to Assess Cancer Patients' Satisfaction With Hospital Quality of Care
RATIONALE: Questionnaires may help determine cancer patients' satisfaction with the quality of care they received in the hospital.
- Trial name
- NCT00045019
- Testing
- quality-of-life assessment
- Where
- 11 sites in Belgium, France and 3 more
- Volunteers
- 795 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Tumor, Solid
Varian ProBeam Proton Therapy System China Clinical Trial (Guangzhou)
This study is prospective, single-center, single-arm objective performance criteria. This trial will be conducted with a total of 47 subjects enrolled.
- Trial name
- NCT06338436
- Testing
- Proton Radiation Therapy System (ProBeam)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Varian, a Siemens Healthineers Company
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Unspecified Adult Solid Tumor, Protocol Specific
17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00248521
- Testing
- alvespimycin hydrochloride
- Where
- 3 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Institute of Cancer Research, United Kingdom